Psoriatic arthritis medical therapy

Jump to navigation Jump to search

Psoriatic arthritis Microchapters


Patient Information


Historical Perspective




Differentiating Psoriatic arthritis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy

Surgical Therapy

Primary prevention

Secondary prevention

Future or Investigational Therapies

Case Studies

Case #1

Psoriatic arthritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Psoriatic arthritis medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriatic arthritis medical therapy

CDC on Psoriatic arthritis medical therapy

Psoriatic arthritis medical therapy in the news

Blogs onPsoriatic arthritis medical therapy

Directions to Hospitals Treating Rheumatoid arthritis

Risk calculators and risk factors for Psoriatic arthritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]


Pharmacologic therapy for psoriatic arthritis includes nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs, tumor necrosis factor (TNF) inhibitors, and interleukin 17 (IL-17) inhibitors, interleukin IL-12/23 inhibitors, and topical glucocorticoid injections. Psoriatic arthritis is a chronic inflammatory arthritis which is manifested as peripheral and axial arthritis, dactylitis, enthesitis and skin and nail involvement. Non - pharmacologic therapy including patient education, weight reduction, and physical therapy may also play an important role in disease management. While treating the patients the primary goal is to maximize the long-term health-related quality of life.

Medical Therapy


  1. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (March 2016). "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update". Ann. Rheum. Dis. 75 (3): 499–510. doi:10.1136/annrheumdis-2015-208337. PMID 26644232.
  2. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P (January 2012). "European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies". Ann. Rheum. Dis. 71 (1): 4–12. doi:10.1136/annrheumdis-2011-200350. PMID 21953336.
  3. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ (September 2009). "Treatment recommendations for psoriatic arthritis". Ann. Rheum. Dis. 68 (9): 1387–94. doi:10.1136/ard.2008.094946. PMC 2719080. PMID 18952643.
  4. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R (July 2011). "Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions". J. Am. Acad. Dermatol. 65 (1): 137–74. doi:10.1016/j.jaad.2010.11.055. PMID 21306785.
  5. Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes IB, Oliver S, Ormerod A, Smith C, Symmons D, Waldron N, McHugh NJ (October 2013). "The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics". Rheumatology (Oxford). 52 (10): 1754–7. doi:10.1093/rheumatology/ket187. PMID 23887065.
  6. Nash P, Clegg DO (March 2005). "Psoriatic arthritis therapy: NSAIDs and traditional DMARDs". Ann. Rheum. Dis. 64 Suppl 2: ii74–7. doi:10.1136/ard.2004.030783. PMC 1766880. PMID 15708943.
  7. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I (2001). "The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide". Clin. Exp. Rheumatol. 19 (1 Suppl 22): S17–20. PMID 11296544.
  8. Mease P (2013). "Methotrexate in psoriatic arthritis". Bull Hosp Jt Dis (2013). 71 Suppl 1: S41–5. PMID 24219040.
  9. 9.0 9.1 Singh YN, Verma KK, Kumar A, Malaviya AN (November 1994). "Methotrexate in psoriatic arthritis". J Assoc Physicians India. 42 (11): 860–2. PMID 7868484.
  10. Steinsson K, Jónsdóttir I, Valdimarsson H (August 1990). "Cyclosporin A in psoriatic arthritis: an open study". Ann. Rheum. Dis. 49 (8): 603–6. PMC 1004173. PMID 2396865.
  11. Keating GM (March 2017). "Apremilast: A Review in Psoriasis and Psoriatic Arthritis". Drugs. 77 (4): 459–472. doi:10.1007/s40265-017-0709-1. PMID 28213862.
  12. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA (October 2005). "Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial". Arthritis Rheum. 52 (10): 3279–89. doi:10.1002/art.21306. PMID 16200601.
  13. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (July 2004). "Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression". Arthritis Rheum. 50 (7): 2264–72. doi:10.1002/art.20335. PMID 15248226.
  14. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (August 2005). "Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial". Ann. Rheum. Dis. 64 (8): 1150–7. doi:10.1136/ard.2004.032268. PMC 1755609. PMID 15677701.
  15. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (April 2009). "Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study". Arthritis Rheum. 60 (4): 976–86. doi:10.1002/art.24403. PMID 19333944.
  16. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (January 2014). "Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)". Ann. Rheum. Dis. 73 (1): 48–55. doi:10.1136/annrheumdis-2013-203696. PMC 3888622. PMID 23942868.
  17. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S (September 2015). "Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial". Lancet. 386 (9999): 1137–46. doi:10.1016/S0140-6736(15)61134-5. PMID 26135703.
  18. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD (January 2017). "Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1". Ann. Rheum. Dis. 76 (1): 79–87. doi:10.1136/annrheumdis-2016-209709. PMC 5264219. PMID 27553214.
  19. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK (August 2013). "Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial". Lancet. 382 (9894): 780–9. doi:10.1016/S0140-6736(13)60594-2. PMID 23769296.
  20. Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (September 2017). "Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis". Ann. Rheum. Dis. 76 (9): 1550–1558. doi:10.1136/annrheumdis-2016-210724. PMC 5561378. PMID 28473423.
  21. Nash P, Lubrano E, Cauli A, Taylor WJ, Olivieri I, Gladman DD (November 2014). "Updated guidelines for the management of axial disease in psoriatic arthritis". J. Rheumatol. 41 (11): 2286–9. doi:10.3899/jrheum.140877. PMID 25362712.
  22. Mease PJ, Armstrong AW (March 2014). "Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis". Drugs. 74 (4): 423–41. doi:10.1007/s40265-014-0191-y. PMC 3958815. PMID 24566842.
  23. Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS (January 2015). "Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation". JAMA Dermatol. 151 (1): 87–94. doi:10.1001/jamadermatol.2014.2983. PMID 25471223.
  24. Rose S, Toloza S, Bautista-Molano W, Helliwell PS (November 2014). "Comprehensive treatment of dactylitis in psoriatic arthritis". J. Rheumatol. 41 (11): 2295–300. doi:10.3899/jrheum.140879. PMID 25362714.

Template:WH Template:WS